Stable Incidence and Poor Survival for HIV-Related Burkitt Lymphoma Among the US Veteran Population During the Antiretroviral Era
- 1 May 2020
- journal article
- conference paper
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 84 (1) , 18-25
Abstract
Background: Despite advances in diagnosis and treatment of both HIV and Burkitt lymphoma (BL), persons living with HIV remain at high risk for BL. We conducted this study to evaluate if there have been any changes in the risk of or survival after BL diagnosis among persons living with HIV during the antiretroviral era. Setting: Veterans living with HIV (VLWH) and age-matched HIV-negative controls receiving care between 1999 and 2016 were retrospectively identified using Veterans Health Administration electronic medical records. Methods: We identified BL diagnoses through Veterans Health Administration Cancer Registry review and International Classification of Diseases, Ninth/Tenth Revisions, codes, and we extracted demographic, lifestyle, and clinical variables from electronic medical record. We estimated hazard ratios (HR) and 95% confidence intervals (CIs) for BL risk and survival using Cox proportional models. Results: We identified 45,299 VLWH. Eighty-four developed BL (incidence rate = 21.2 per 100,000 person years; CI: 17.1 to 26.3). Median CD4 count at BL diagnosis was 238 cells per milliliter (SD: 324.74) and increased over time. Survival was truncated in VLWH with BL (P < 0.05). The risk of BL in VLWH was 38% less in blacks compared with whites (HR: 0.620; CI: 0.393 to 0.979; P = 0.0401). VLWH with an undetectable viral load for at least 40% of follow-up were 74% less likely to develop BL (HR: 0.261; CI: 0.143 to 0.478; P < 0.0001) and 86% less likely to die after diagnosis (HR: 0.141; CI: 0.058 to 0.348; P < 0.0001). Conclusions: BL incidence among VLWH did not improve between 2000 and 2016. Survival after BL diagnosis in VLWH remains dismal as compared with their HIV-negative counterparts, although veterans with prolonged periods of undetectable viral load had improved prognosis.Keywords
This publication has 28 references indexed in Scilit:
- Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy EraJNCI: Journal of the National Cancer Institute, 2013
- AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?Blood, 2010
- Cancer as a Cause of Death among People with AIDS in the United StatesClinical Infectious Diseases, 2010
- Immunologic and Virologic Predictors of AIDS-Related Non-Hodgkin Lymphoma in the Highly Active Antiretroviral Therapy EraJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapyAIDS, 2009
- Trends in cancer risk among people with AIDS in the United States 1980–2002AIDS, 2006
- Factors Associated with the Occurrence of AIDS-Related Non-Hodgkin Lymphoma in the Era of Highly Active Antiretroviral Therapy: Aquitaine Cohort, FranceClinical Infectious Diseases, 2006
- AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre–Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard ChemotherapyJournal of Clinical Oncology, 2005
- Intensive chemotherapy with cyclophosphamide, doxorubicin, high‐dose methotrexate/ifosfamide, etoposide, and high‐dose cytarabine (CODOX‐M/IVAC) for human immunodeficiency virus–associated Burkitt lymphomaCancer, 2003
- Definition of two distinct types of AIDS‐associated non‐Hodgkin lymphomaBritish Journal of Haematology, 1990